Nitric oxide modulates HIV-1 replication

Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology

Volumn 22, Issue 1, 1999, Pages 1-9

  Mannick, Joan B ^a,c   Stamler, Jonathan S ^b   Teng, Edna ^a   Simpson, Neal ^a   Lawrence, John ^a   Jordan, Jeff ^a   Finberg, Robert W ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

HIV 1; Nitric oxide; Peripheral blood mononuclear cells; U1 cells; Virus replication

Indexed keywords

CYCLIC GMP; NITRIC OXIDE; THIOL DERIVATIVE; VIRUS PROTEIN; ZIDOVUDINE;

ARTICLE; CORONARY ARTERY DISEASE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION; VIRUS REACTIVATION; VIRUS REPLICATION;

EID: 0344980379     PISSN: 10779450     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042560-199909010-00001     Document Type: Article

References (62)

1. Stamler JS, Jaraki O, Osborne J, et al. Nitric oxide circulates in mammalian plasma primarily as an S-nitroso adduct of serum albumin. Proc Natl Acad Sci USA 1992;89:7674-7.
2. Stamler JS, Jia L, Eu JP, et al. Blood flow regulation by S-nitrosohemoglobin in the physiological oxygen gradient. Science 1997;276:2034-7.
3. Nathan C. Nitric oxide as a secretory product of mammalian cells. FASEB J 1992;6:3051-64.
4. Lipton SA, Choi YB, Pan ZH, et al. A redox-based mechanism for the neuroprotective and neurodestructive effects of nitric oxide and related nitroso-compounds [see comments]. Nature 1993;364:626-32.
5. Albina JE, Cui S, Mateo RB, Reichner JS. Nitric oxide-mediated apoptosis in murine peritoneal macrophages. J Immunol 1993;150: 5080-5.
6. Mannick JB, Asano K, Izumi K, Kieff E, Stamler JS. Nitric oxide produced by human B lymphocytes inhibits apoptosis and Epstein-Barr virus reactivation. Cell 1994:79:1137-46.
7. Genaro AM, Hortelano S, Alvarez A, Martinez C, Bosca L. Splenic B lymphocyte programmed cell death is prevented by nitric oxide release through mechanisms involving sustained Bcl-2 levels. J Clin Invest 1995;95:1884-90.
8. Lander HM, Sehajpal P, Levine DM, Novogrodsky A. Activation of human peripheral blood mononuclear cells by nitric oxide-generating compounds. J Immunol 1993;150:1509-16.
9. Peng HB, Libby P, Liao JK. Induction and stabilization of I kappa B alpha by nitric oxide mediates inhibition of NF-kappa B. J Biol Chem 1995;270:14214-9.
10. Croen KD. Evidence for antiviral effect of nitric oxide. Inhibition of herpes simplex virus type 1 replication. J Clin Invest 1993;91: 2446-52.
11. Karupiah G, Xie QW, Buller RM, Nathan C, Duarte C, MacMicking JD. Inhibition of viral replication by interferon-gamma-induced nitric oxide synthase. Science 1993;261:1445-8.
12. Bi Z, Reiss CS. Inhibition of vesicular stomatitis virus infection by nitric oxide. J Virol 1995;69:2208-13.
13. Akarid K, Sinet M, Desforges B, Gougerot-Pocidalo MA. Inhibitory effect of nitric oxide on the replication of a murine retrovirus in vitro and in vivo. J Virol 1995;69:7001-5.
14. Lowenstein CJ, Hill SL, Lafond-Walker A, et al. Nitric oxide inhibits viral replication in murine myocarditis. J Clin Invest 1996; 97:1837-43.
15. Guillemard E, Geniteau-Legendre M, Kergot R, et al. Activity of nitric oxide-generating compounds against encephalomyocarditis virus. Antimicrob Agents Chemother 1996;40:1057-9.
16. Komatsu T, Bi Z, Reiss CS. Interferon-gamma induced type I nitric oxide synthase activity inhibits viral replication in neurons. J Neuroimmunol 1996;68:101-8.
17. Kreil TR, Eibl MM. Nitric oxide and viral infection: NO antiviral activity against a flavivirus in vitro, and evidence for contribution to pathogenesis in experimental infection in vivo. Virology 1996; 219:304-6.
18. Lin YL, Huang YL, Ma SH, et al. Inhibition of Japanese encephalitis virus infection by nitric oxide: antiviral effect of nitric oxide on RNA virus replication. J Virol 1997;71:5227-35.
19. Lopez-Guerrero JA, Rayet B, Tuynder M, Rommelaere J, Dinsart C. Constitutive activation of U937 promonocytic cell clones selected for their resistance to parvovirus H-1 infection. Blood 1997; 89:1642-53.
20. Lopez-Guerrero JA, Carrasco L. Effect of nitric oxide on poliovirus infection of two human cell lines. J Virol 1998;72:2538-40.
21. Melkova Z, Esteban M. Inhibition of vaccinia virus DNA replication by inducible expression of nitric oxide synthase. J Immunol 1995;155:5711-8.
22. Pope M, Marsden PA, Cole E, et al. Resistance to murine hepatitis virus strain 3 is dependent on production of nitric oxide. J Virol 1998;72:7084-90.
23. Reiss CS, Komatsu T. Does nitric oxide play a critical role in viral infections? J Virol 1998;72:4547-51.
24. Sanders SP, Siekierski ES, Porter JD, Richards SM, Proud D. Nitric oxide inhibits rhinovirus-induced cytokine production and viral replication in a human respiratory epithelial cell line. J Virol 1998;72:934-42.
25. Tay CH, Welsh RM. Distinct organ-dependent mechanisms for the control of murine cytomegalovirus infection by natural killer cells. J Virol 1997;71:267-75.
26. Zaragoza C, Ocampo CJ, Saura M, McMillan A, Lowenstein CJ. Nitric oxide inhibition of coxsackievirus replication in vitro. J Clin Invest 1997;100:1760-7.
27. Bukrinsky MI, Nottet HS, Schmidtmayerova H, et al. Regulation of nitric oxide synthase activity in human immunodeficiency virus type 1 (HIV-1)-infected monocytes: implications for HIV-associated neurological disease. J Exp Med 1995;181:735-45.
28. Evans TG, Rasmussen K, Wiebke G, Hibbs JB, Jr. Nitric oxide synthesis in patients with advanced HIV infection. Clin Exp Immunol 1994;97:83-6.
29. Torre D, Ferrario G, Bonetta G, Speranza F, Zeroli C. Production of nitric oxide from peripheral blood mononuclear cells and polymorphonuclear leukocytes of patients with HIV-1 [letter]. AIDS 1995;9:979-80.
30. Zangerle R, Fuchs D, Reibnegger G, et al. Serum nitrite plus nitrate in infection with human immunodeficiency virus type-1. Immunobiology 1995;193:59-70.
31. Torre D, Ferrario G, Speranza F, Martegani R, Zeroli C. Increased levels of nitrite in the sera of children infected with human immunodeficiency virus type 1. Clin Infect Dis 1996;22:650-653.
32. Dawson VL, Dawson TM, Uhl GR, Snyder SH. Human immunodeficiency virus type 1 coat protein neurotoxicity mediated by nitric oxide in primary cortical cultures. Proc Natl Acad Sci USA 1993;90:3256-9.
33. Koka P, He K, Zack JA, et al. Human immunodeficiency virus 1 envelope proteins induce interleukin 1, tumor necrosis factor alpha, and nitric oxide in glial cultures derived from fetal, neonatal, and adult human brain. J Exp Med 1995;182:941-51.
34. Adamson DC, Wildemann B, Sasaki M, et al. Immunologic NO synthase: elevation in severe AIDS dementia and induction by HIV-1 gp41. Science 1996;274:1917-21.
35. Ouaaz F, Ruscetti FW, Dugas B, et al. Role of IgE immune complexes in the regulation of HIV-1 replication and increased cell death of infected U1 monocytes: involvement of CD23/Fc epsilon RII-mediated nitric oxide and cyclic AMP pathways. Mol Med 1996;2:38-49.
36. Hermann E, Idziorek T, Kusnierz JP, Mouton Y, Capron A, Bahr GM. Role of nitric oxide in the regulation of lymphocyte apoptosis and HIV-1 replication. Int J Immunopharmacol 1997;19:387-97.
37. Persichini T, Colasanti M, Fraziano M, Colizzi V, Ascenzi P, Lauro GM. Nitric oxide inhibits HIV-1 replication in human astrocytoma cells. Biochem Biophys Res Commun 1999;254:200-2.
38. Persichini T, Colasanti M, Lauro GM, Ascenzi P. Cysteine nitrosylation inactivates the HIV-1 protease. Biochem Biophys Res Commun 1998;250:575-6.
39. Heagy W, Crumpacker C, Lopez PA, Finberg RW. Inhibition of immune functions by antiviral drugs. J Clin Invest 1991;87:1916-24.
40. Ou CY, Kwok S, Mitchell SW, et al. DNA amplification for direct detection of HIV-1 in DNA of peripheral blood mononuclear cells. Science 1988;239:295-7 [published erratum appears in Science 1988;240:240].
41. Coligan JE, Kruisbeek AM, Margulies DH, Shevach EM, Strober W, eds. Current Protocols in Immunology. John Wiley & Sons, 1993.
42. Hoffman RA, Langrehr JM, Billiar TR, Curran RD, Simmons RL. Alloantigen-induced activation of rat splenocytes is regulated by the oxidative metabolism of L-arginine. J Immunol 1990;145: 2220-6.
43. Albina JE, Henry W, Jr. Suppression of lymphocyte proliferation through the nitric oxide synthesizing pathway. J Surg Res 1991; 50:403-9.
44. Mills CD. Molecular basis of suppressor macrophages. Arginine metabolism via the nitric oxide synthetase pathway. J Immunol 1991;146:2719-23.
45. Folks T, Kelly J, Benn S, et al. Susceptibility of normal human lymphocytes to infection with HTLV-III/LAV. J Immunol 1986; 136:4049-53.
46. Zagury D, Bernard J, Leonard R, Cheynier R, Feldman M, Sarin PS. Long-term cultures of HTLV-III-infected T cells: a model of cytopathology. Science 1986;231:850-3.
47. Zack JA, Cann AJ, Lugo JP, Chen IS. HIV-1 production from infected peripheral blood T cells after HTLV-I. Science 1988;240: 1026-9.
48. Gaston B, Reilly J, Drazen JM, et al. Endogenous nitrogen oxides and bronchodilator S-nitrosothiols in human airways. Proc Natl Acad Sci USA 1993;90:10957-61.
49. Pacelli R, Taira J, Cook JA, Wink DA, Krishna MC. Hydroxyurea reacts with heme proteins to generate nitric oxide. Lancet 1996; 347:900.
50. Jiang J, Jordan SJ, Barr DP, Gunther MR, Maeda H, Mason RP. In vivo production of nitric oxide in rats after administration of hydroxyurea. Mol Pharmacol 1997;52:1081-6.
51. Lori F, Malykh A, Cara A, et al. Hydroxyurea as an inhibitor of human immunodeficiency virus-type 1 replication. Science 1994; 266:801-5.
52. Giacca M, Borella S, Calderazzo F, et al. Synergistic antiviral action of ribonucleotide reductase inhibitors and 3′-azido-3′-deoxythymidine on HIV type 1 infection in vitro. AIDS Res Hum Retroviruses 1996;12:677-82.
53. Lori F, Malykh AG, Foli A, et al. Combination of a drug targeting the cell with a drug targeting the virus controls human immunodeficiency virus type 1 resistance. AIDS Res Hum Retroviruses 1997;13:1403-9.
54. Palmer S, Cox S. Increased activation of the combination of 3′-azido-3′-deoxythymidine and 2′-deoxy-3′-thiacytidine in the presence of hydroxyurea. Antimicrob Agents Chemother 1997;41: 460-4.
55. Kwon NS, Stuehr DJ, Nathan CF. Inhibition of tumor cell ribonucleotide reductase by macrophage-derived nitric oxide. J Exp Med 1991;174:761-7.
56. Chun TW, Stuyver L, Mizell SB, et al. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci USA 1997;94:13193-7.
57. Orucevic A, Lala PK. NG-nitro-L-arginine methyl ester, an inhibitor of nitric oxide synthesis, ameliorates interleukin 2-induced capillary leakage and reduces tumour growth in adenocarcinomabearing mice. Br J Cancer 1996;73:189-96.
58. Citterio G, Pellegatta F, Lucca GD, et al. Plasma nitrate plus nitrite changes during continuous intravenous infusion interleukin 2. Br J Cancer 1996;74:1297-1301.
59. Feelisch M, Stamler JS. Donors of Nitrogen Oxide. Methods in Nitric Oxide Research. New York: John Wiley & Sons, 1996.
60. Finzi D, Hermankova M, Pierson T, et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 1997;278:1295-1300.
61. Wong JK, Hezareh M, Gunthard HF, et al. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 1997;278:1291-5.
62. Kobzik L, Bredt DS, Lowenstein CJ, et al. Nitric oxide synthase in human and rat lung: immunocytochemical and histochemical localization. Am J Respir Cell Mol Biol 1993;9:371-7.